...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway
【24h】

Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway

机译:降低血小板细胞内抗氧化能力通过ROS-NLRP3-胱天蛋白酶-1途径有助于原发性免疫血小板减少症

获取原文
获取原文并翻译 | 示例

摘要

Primary immune thrombocytopenia (ITP) is a common acquired autoimmune hemorrhagic disease characterized by a low platelet count and increased risk of bleeding. However, some patients do not respond well to current therapeutic approaches. Further studies on pathogenesis and pathophysiology of ITP are needed to discover new therapeutic targets. We explored the role of enhanced intracellular oxidative stress and NLRP3 inflammasome activation of platelets in ITP. The expression of NLRP3 inflammasome was assessed in platelets from active ITP patients and healthy donors. Both the mRNA and protein expression level of platelet NLRP3 inflammasome was upregulated in ITP patients compared with healthy donors. Besides, the elevated caspase-1 activity and increased co-localization of NLRP3 and its adaptor molecule ASC indicated activation of NLRP3 inflammasome in ITP platelets. Significantly decreased intracellular antioxidant capacity was observed in ITP platelets. H2O2 supplementation elevated the expression of NLRP3 inflammasome and increased IL-1 beta secretion in ITP platelets. Preincubating ITP platelets with NAC down-regulated the expression of NLRP3 inflammasome. Pretreating ITP platelets with NLRP3 inhibitor MCC950 or caspase-1 inhibitor Z-YVAD-FMK significantly reduced the proportion of pyroptotic cells in H2O2-treated ITP platelets and suppressed IL-1 beta secretion in supernatants. Hence, platelet NLRP3 inflammasome activation resulted from reduced intracellular antioxidant capacity plays a critical role in ITP and might have potential diagnostic or therapeutic implications.
机译:原发性免疫性血小板减少症(ITP)是一种常见的获得性自身免疫性出血性疾病,其特点是血小板计数低,出血风险增加。然而,一些患者对目前的治疗方法反应不佳。ITP的发病机制和病理生理学需要进一步研究,以发现新的治疗靶点。我们探讨了增强的细胞内氧化应激和血小板NLRP3炎症体激活在ITP中的作用。在活动性ITP患者和健康献血者的血小板中评估NLRP3炎性体的表达。与健康供体相比,ITP患者血小板NLRP3炎性体的mRNA和蛋白质表达水平均上调。此外,升高的caspase-1活性和NLRP3及其衔接分子ASC的共定位增加表明ITP血小板中NLRP3炎症小体的激活。ITP血小板的细胞内抗氧化能力显著降低。补充H2O2可提高ITP血小板中NLRP3炎症体的表达,并增加IL-1β的分泌。用NAC预孵育ITP血小板可下调NLRP3炎症体的表达。用NLRP3抑制剂MCC950或半胱天冬酶-1抑制剂Z-YVAD-FMK预处理ITP血小板可显著降低H2O2处理的ITP血小板中的焦脱细胞比例,并抑制上清液中的IL-1β分泌。因此,细胞内抗氧化能力降低导致的血小板NLRP3炎性体激活在ITP中起着关键作用,可能具有潜在的诊断或治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号